Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00296530 · ClinicalTrials.gov registry record · Phase 4
Study Of Patients With Allergic Rhinitis And Asthma
A Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 4
- Development phase
- 600
- Enrollment target
- 20
- Study locations
NCT00296530: Completed Phase 4 study of Asthma, sponsored by GlaxoSmithKline.
NCT00296530 is a Phase 4 study of Asthma that has completed, run by GlaxoSmithKline. The registered enrollment target is 600 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00296530, a Phase 4 study of Asthma, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.
Conditions Studied
Interventions
- DRUG montelukast
- DRUG fluticasone propionate
- DRUG fluticasone propionate/salmeterol
Study Locations (20)
California
- GSK Investigational Site - Fountain Valley
- GSK Investigational Site - Huntington Beach
- GSK Investigational Site - Long Beach
- GSK Investigational Site - Los Angeles
- GSK Investigational Site - Orange
- GSK Investigational Site - Palmdale
- GSK Investigational Site - Riverside
- GSK Investigational Site - San Diego
- GSK Investigational Site - San Jose
- GSK Investigational Site - Stockton
- GSK Investigational Site - Vista
Colorado
- GSK Investigational Site - Colorado Springs
- GSK Investigational Site - Denver
- GSK Investigational Site - Denver
- GSK Investigational Site - Wheat Ridge
Florida
- GSK Investigational Site - Coral Gables
- GSK Investigational Site - Miami
Alabama
- GSK Investigational Site - Ozark
Arizona
- GSK Investigational Site - Tempe
Arkansas
- GSK Investigational Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2005-09 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00296530 record still lists
NCT00296530 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 3 interventions - of which montelukast is the first listed.
NCT00296530 names 20 study sites across 6 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT00296530 about?
NCT00296530 is a clinical study titled "Study Of Patients With Allergic Rhinitis And Asthma". This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs u...
What is the current status of trial NCT00296530?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 600 participants. The study started on 2005-09. Estimated completion is 2007-07.
What conditions does trial NCT00296530 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT00296530?
The interventions under investigation include: montelukast (DRUG), fluticasone propionate (DRUG), fluticasone propionate/salmeterol (DRUG).
Who is sponsoring clinical trial NCT00296530?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00296530 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00296530's enrollment target sits among peer trials
600 68th of 374 higher than 306 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia